


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 2

Complete If Known

Application Number	09/996,588
Filing Date	November 30, 2001
First Named Inventor	Glenn J. Dorin
Art Unit	1653
Examiner Name	Rita Mitra
Attorney Docket Number	012441.00013

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Rainer Rudolph, "Successful Protein Folding on a Industrial Scale", Protein Engineering: Principles and Practice, Chapter 10, pps. 283-298, dated 1998	
		Rudolph & Lillie, "In vitro folding of inclusion-body proteins", Folding of Acidic Fibroblast Growth Factor, FASEB J., 10, pps. 49-56, date unknown	
		Dabora et al., "Effect of Polyanions on the Refolding of Human Acidic Fibroblast Growth Factor", The Journal Of Biological Chemistry, Vol. 266, No. 35, pps. 23637-23640, dated December 15, 1991	
		Bernhard Fisher et al., "Isolation, Renaturation, and Formation of Disulfide Bonds of Eukaryotic Proteins Expressed in Escherichia coli as Inclusion Bodies, Biotechnology and Bioengineering, Vol. 41, pps. 3-13, dated 1993	
		J. Harenberg, et al., "Tissue factor pathway inhibitor: proposed heparin recognition region, Blood Coagulation and Fibrinolysis, Vol. 6, Supp. No. 1, pps. S50-S56, dated 1995	
		Mark E. Gustafson et al., "Renaturation and Purification of Human Tissue Factor Pathway Inhibitor Expressed in Recombinant E. coli, Protein Expression and Purification, Vol. 5, pps. 233-241, dated 1994	

Examiner
Signature

R. Mitra

Date
Considered

2/3/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.